Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation: Comparison of aspirin alone versus combined ticlopidine and aspirin therapy

Remo Albiero, Patrick Hall, Akira Itoh, Simonetta Blengino, Shigeru Nakamura, Giovanni Martini, Massimo Ferraro, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Background: Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present. However, it is unknown whether ticlopidine combined with aspirin is superior to aspirin alone in preventing stent thrombosis. Methods and Results: From March 1993 through July 1995, 801 consecutive patients assigned to receive either aspirin therapy alone (ASA, 264 patients, 348 lesions) or a combination of ticlopidine and aspirin (TIC-ASA, 537 patients, 737 lesions) after a successful stent insertion, in most accomplished with intravascular ultrasound guidance, were evaluated retrospectively. At 1 month, there was no difference in the ASA group compared with the TIC-ASA group in the rate of any stent thrombosis (1.9% versus 1.9%; P=1), subacute stent thrombosis (1.9% versus 1.3%; P=.5), cumulative major adverse clinical events (1.9% versus 2.0%; P=1), and peripheral vascular complications (0.5% versus 0.2%; P=.3). Medication side effects that required termination of antiplatelet therapy occurred only in 1.9% of patients in the TIC-ASA group (P=.04). Conclusions: At 1-month clinical follow-up, stent thrombosis and other adverse clinical outcomes were not significantly different between the ASA and TIC-ASA groups. Medication side effects occurred only in patients treated with ticlopidine. These results provide further evidence of the safety of treatment with antiplatelet therapy only after optimal stent implantation and support the efficacy of aspirin alone in preventing stent thrombosis.

Original languageEnglish
Pages (from-to)1145-1156
Number of pages12
JournalCirculation
Volume95
Issue number5
Publication statusPublished - 1997

Fingerprint

Ticlopidine
Aspirin
Stents
Thrombosis
Therapeutics
Blood Vessels
Coronary Vessels

Keywords

  • aspirin
  • coronary disease
  • platelet aggregation inhibitors
  • stents
  • ultrasonics

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation : Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. / Albiero, Remo; Hall, Patrick; Itoh, Akira; Blengino, Simonetta; Nakamura, Shigeru; Martini, Giovanni; Ferraro, Massimo; Colombo, Antonio.

In: Circulation, Vol. 95, No. 5, 1997, p. 1145-1156.

Research output: Contribution to journalArticle

Albiero, Remo ; Hall, Patrick ; Itoh, Akira ; Blengino, Simonetta ; Nakamura, Shigeru ; Martini, Giovanni ; Ferraro, Massimo ; Colombo, Antonio. / Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation : Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. In: Circulation. 1997 ; Vol. 95, No. 5. pp. 1145-1156.
@article{b461b07a8f7d4e62bc15bc30bd4820db,
title = "Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation: Comparison of aspirin alone versus combined ticlopidine and aspirin therapy",
abstract = "Background: Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present. However, it is unknown whether ticlopidine combined with aspirin is superior to aspirin alone in preventing stent thrombosis. Methods and Results: From March 1993 through July 1995, 801 consecutive patients assigned to receive either aspirin therapy alone (ASA, 264 patients, 348 lesions) or a combination of ticlopidine and aspirin (TIC-ASA, 537 patients, 737 lesions) after a successful stent insertion, in most accomplished with intravascular ultrasound guidance, were evaluated retrospectively. At 1 month, there was no difference in the ASA group compared with the TIC-ASA group in the rate of any stent thrombosis (1.9{\%} versus 1.9{\%}; P=1), subacute stent thrombosis (1.9{\%} versus 1.3{\%}; P=.5), cumulative major adverse clinical events (1.9{\%} versus 2.0{\%}; P=1), and peripheral vascular complications (0.5{\%} versus 0.2{\%}; P=.3). Medication side effects that required termination of antiplatelet therapy occurred only in 1.9{\%} of patients in the TIC-ASA group (P=.04). Conclusions: At 1-month clinical follow-up, stent thrombosis and other adverse clinical outcomes were not significantly different between the ASA and TIC-ASA groups. Medication side effects occurred only in patients treated with ticlopidine. These results provide further evidence of the safety of treatment with antiplatelet therapy only after optimal stent implantation and support the efficacy of aspirin alone in preventing stent thrombosis.",
keywords = "aspirin, coronary disease, platelet aggregation inhibitors, stents, ultrasonics",
author = "Remo Albiero and Patrick Hall and Akira Itoh and Simonetta Blengino and Shigeru Nakamura and Giovanni Martini and Massimo Ferraro and Antonio Colombo",
year = "1997",
language = "English",
volume = "95",
pages = "1145--1156",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation

T2 - Comparison of aspirin alone versus combined ticlopidine and aspirin therapy

AU - Albiero, Remo

AU - Hall, Patrick

AU - Itoh, Akira

AU - Blengino, Simonetta

AU - Nakamura, Shigeru

AU - Martini, Giovanni

AU - Ferraro, Massimo

AU - Colombo, Antonio

PY - 1997

Y1 - 1997

N2 - Background: Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present. However, it is unknown whether ticlopidine combined with aspirin is superior to aspirin alone in preventing stent thrombosis. Methods and Results: From March 1993 through July 1995, 801 consecutive patients assigned to receive either aspirin therapy alone (ASA, 264 patients, 348 lesions) or a combination of ticlopidine and aspirin (TIC-ASA, 537 patients, 737 lesions) after a successful stent insertion, in most accomplished with intravascular ultrasound guidance, were evaluated retrospectively. At 1 month, there was no difference in the ASA group compared with the TIC-ASA group in the rate of any stent thrombosis (1.9% versus 1.9%; P=1), subacute stent thrombosis (1.9% versus 1.3%; P=.5), cumulative major adverse clinical events (1.9% versus 2.0%; P=1), and peripheral vascular complications (0.5% versus 0.2%; P=.3). Medication side effects that required termination of antiplatelet therapy occurred only in 1.9% of patients in the TIC-ASA group (P=.04). Conclusions: At 1-month clinical follow-up, stent thrombosis and other adverse clinical outcomes were not significantly different between the ASA and TIC-ASA groups. Medication side effects occurred only in patients treated with ticlopidine. These results provide further evidence of the safety of treatment with antiplatelet therapy only after optimal stent implantation and support the efficacy of aspirin alone in preventing stent thrombosis.

AB - Background: Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present. However, it is unknown whether ticlopidine combined with aspirin is superior to aspirin alone in preventing stent thrombosis. Methods and Results: From March 1993 through July 1995, 801 consecutive patients assigned to receive either aspirin therapy alone (ASA, 264 patients, 348 lesions) or a combination of ticlopidine and aspirin (TIC-ASA, 537 patients, 737 lesions) after a successful stent insertion, in most accomplished with intravascular ultrasound guidance, were evaluated retrospectively. At 1 month, there was no difference in the ASA group compared with the TIC-ASA group in the rate of any stent thrombosis (1.9% versus 1.9%; P=1), subacute stent thrombosis (1.9% versus 1.3%; P=.5), cumulative major adverse clinical events (1.9% versus 2.0%; P=1), and peripheral vascular complications (0.5% versus 0.2%; P=.3). Medication side effects that required termination of antiplatelet therapy occurred only in 1.9% of patients in the TIC-ASA group (P=.04). Conclusions: At 1-month clinical follow-up, stent thrombosis and other adverse clinical outcomes were not significantly different between the ASA and TIC-ASA groups. Medication side effects occurred only in patients treated with ticlopidine. These results provide further evidence of the safety of treatment with antiplatelet therapy only after optimal stent implantation and support the efficacy of aspirin alone in preventing stent thrombosis.

KW - aspirin

KW - coronary disease

KW - platelet aggregation inhibitors

KW - stents

KW - ultrasonics

UR - http://www.scopus.com/inward/record.url?scp=0031018569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031018569&partnerID=8YFLogxK

M3 - Article

C2 - 9054843

AN - SCOPUS:0031018569

VL - 95

SP - 1145

EP - 1156

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -